Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.48 | N/A | +2.08% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.48 | N/A | +2.08% |
| Revenue | N/A | N/A | N/A |
Tone: Confident
Management expressed confidence in the company's ongoing performance. They highlighted strong results in their core products and a commitment to future growth.
The company continues to show strong performance in key therapeutic areas.
We are committed to delivering value to our shareholders.
AbbVie's earnings report showed a positive surprise in EPS, which likely contributed to the stock's significant rise of 13.77%. The management's confident tone and focus on strong performance in key areas suggest that the company is on a solid path moving forward. However, the lack of revenue data and guidance may leave some investors cautious.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PROLOGIS INC REIT
Jan 23, 2018